2
Announcements
Trials
Browse
Landscape
Status
Available
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
31
Observational
4
Expanded_access
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Conditions
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Interventions
3-Iodobenzylguanidine
9
Amifampridine
6
nilotinib
5
Magnetic Resonance Spectroscopy
5
Cyclophosphamide
5
trametinib
4
pembrolizumab
4
gallium 68 PSMA-11
4
fludarabine
4
elotuzumab
4
dabrafenib
4
Nivolumab
4
Bortezomib
4
Afatinib
4
venetoclax
3
regorafenib
3
midostaurin
3
fludarabine phosphate
3
TIC10 compound
3
Sunitinib
3
Prednisone
3
Lenalidomide
3
Ipilimumab
3
Everolimus
3
Dexamethasone
3
Crizotinib
3
Capecitabine
3
Axitinib
3
Alpelisib
3
Abiraterone Acetate
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Expanded_access
×
asciminib
×
Clear all
NCT04360005
2025-12-05
Managed Access Programs for ABL001, Asciminib
Novartis
Available